Reagan and Johnson engaged in another classic — an extra-inning and 3½ hour walkoff that knotted up the race for the District 28-6A championship.
Johnson Jaguars Jason Anderson reacts after scoring. Reagan defeated Johnson 6-5 in nine innings in a District 28-6A baseball showdown at North East Sports Park on Tuesday, April 18, 2023.Reagan and Johnson went nine innings over 3½ hours Tuesday night before the Rattlers finally walked it off.
“I’m rounding first and I’m thinking ‘Get over his head. Make a mistake. Come on. Do something here,’ and it ended up happening,” Roy said. Reagan and Johnson are now tied for first in the district standings at 12-1 with three games left in the regular season.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Johnson & Johnson beats Q1 consensus estimates and raises guidanceJohnson & Johnson’s stock rose 1.4% in premarket trade Tuesday, after the consumer health and pharma company beat consensus estimates for its first quarter...
Consulte Mais informação »
JNJ Stock Price | Johnson & Johnson Stock - Investing.comGet today's JNJ stock price and latest Johnson & Johnson stock news as well as JNJ real-time stock quotes, technical analysis, full financials and more.
Consulte Mais informação »
Johnson & Johnson Posts Higher Quarterly Sales, Raises 2023 OutlookFirst-quarter earnings were wiped out by a $6.9 billion charge tied to litigation and other costs from its Covid-19 vaccine commitments.
Consulte Mais informação »
Stocks making the biggest moves premarket: Johnson & Johnson, Goldman Sachs, Sunrun and moreShares of Goldman Sachs shed nearly 4% after missing revenue estimates in its first-quarter earnings released before Tuesday's opening bell.
Consulte Mais informação »
Johnson & Johnson beats on earnings and revenue, raises full-year guidanceEARNINGS: J&J reported adjusted earnings and revenue that topped Wall Street’s expectations, and lifted its full-year forecast. CFO Joseph Wolk joins us to discuss.
Consulte Mais informação »
Why the pros say there's still a lot of upside to Johnson & Johnson after earnings beatAnalysts and investors took to CNBC to discuss the latest action for Johnson & Johnson shares.
Consulte Mais informação »